Aurora Cannabis Inc. reported fiscal Q2 2026 results that surpassed consensus estimates, with net revenue of C$90.4 million—an 11 % year‑over‑year increase—and adjusted earnings per share of C$0.09, beating the consensus of C$0.03 by C$0.06 (a 200 % lift). The company’s medical‑cannabis segment drove the upside, with net revenue of C$70.5 million, up 15 % from C$60.5 million in the same quarter a year earlier.
Consumer‑cannabis revenue fell 34 % to C$6.9 million, reflecting Aurora’s deliberate shift toward higher‑margin medical products. The company’s adjusted EBITDA rose 52 % to C$15.4 million, while the adjusted gross margin expanded to 61 % from 54 % a year earlier, underscoring tighter cost control and a more favorable product mix. Aurora’s cash balance stood at C$141.9 million, reinforcing its debt‑free status and providing a buffer for future investment.
Management guided that consolidated net revenue will continue to grow year‑over‑year, driven primarily by 8 %‑12 % growth in the Global Medical Cannabis segment. The company also reaffirmed its commitment to strong free‑cash‑flow generation and to ongoing investment in GMP‑certified manufacturing and genetics capabilities, positioning it to capture expanding international markets.
The results reinforce Aurora’s medical‑first strategy. The 15 % jump in medical‑cannabis revenue and the 52 % rise in adjusted EBITDA demonstrate that the company’s focus on high‑margin products is translating into both top‑line and bottom‑line gains. The decline in consumer revenue is a strategic choice rather than a weakness, allowing Aurora to allocate resources to markets where it holds a competitive advantage.
Investors responded positively to the earnings, with analysts noting the company’s robust performance and its strong cash position. The beat on both revenue and EPS, combined with the company’s clear guidance and strategic focus, suggests confidence in Aurora’s continued growth trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.